Minimizing the impact of HCV lookback by using RIBA HCV 3.0 SIA.

被引：0
|
作者：
Tegtmeier, GE [1 ]
Edwards, RL [1 ]
Henderson, SE [1 ]
Wright, JE [1 ]
Menitove, JE [1 ]
机构：
[1] Community Blood Ctr, Kansas City, MO USA
来源：
TRANSFUSION | 1998年 / 38卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S352
引用
收藏
页码：93S / 93S
页数：1
相关论文
共 50 条
  • [21] DETECTION OF ANTI-HCV SEROCONVERSION WITH NEW 3RD-GENERATION HCV ELISA (ELISA-3) AND IMMUNOBLOT (RIBA-3.0)
    VANDERPOEL, CL
    VRIELINK, H
    REESINK, HW
    QUAN, S
    POLITO, A
    ZAAIJER, HL
    LELIE, PN
    [J]. TRANSFUSION, 1993, 33 (09) : S33 - S33
  • [22] HCV EIA and RIBA 3.0 seroreversion among subjects in a follow-up study of HCV seropositive blood donors who tested positive or negative for HCV RNA by minipool-NAT screening
    Tobler, L. H.
    Murphy, E. L., III
    Bahrami, S. H.
    Lewithan, P. M.
    Andrews, W. W.
    Ziermann, R.
    Busch, M. P.
    [J]. TRANSFUSION, 2007, 47 (03) : 30A - 30A
  • [23] Misclassification of HCV-viremic blood donors as indeterminate by RIBA 3.0 because of human superoxide dismutase reactivity
    Tobler, LH
    Stramer, SL
    Kleinman, SH
    Brodsky, JP
    Todd, DS
    Busch, MP
    [J]. TRANSFUSION, 2001, 41 (12) : 1625 - 1626
  • [24] Misclassification of HCV viremic blood donors as indeterminate by RIBA 3.0 due to human superoxide dismutase (hSOD)reactivity
    Tobler, LH
    Stramer, SL
    Kleinman, SH
    Brodsky, J
    Todd, D
    Wu, Y
    [J]. TRANSFUSION, 2000, 40 (10) : 78S - 78S
  • [25] RESOLUTION OF C22-3 INDETERMINATE DONORS WITH A PROTOTYPE RIBA(TM) STRIP IMMUNOASSAY (P-RIBA SIA) FOR ANTIBODIES TO HEPATITIS-C VIRUS (HCV)
    TEGTMEIER, GE
    PARKS, LH
    BLOSSER, JK
    TUCK, PA
    BAYER, WL
    DINELLO, RD
    QUAN, S
    POLITO, A
    [J]. TRANSFUSION, 1992, 32 (08) : S74 - S74
  • [26] Minimizing the impact of autologous donations on pooled nucleic acid testing for HCV
    Addington, MJ
    Plumlee, R
    [J]. TRANSFUSION, 2003, 43 (09) : 158A - 159A
  • [27] Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis c virus (HCV) RNA detection and quantification: Impact on diagnosis and treatment of HCV infections
    Desombere, I
    Van Vlierberghe, H
    Couvent, S
    Clinckspoor, F
    Leroux-Roels, G
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (06) : 2590 - 2597
  • [28] The financial impact of the first variance to eliminate RIBA supplemental testing for HCV-NAT positive donors
    Pratt, ML
    Thomas, KJ
    [J]. TRANSFUSION, 2005, 45 (03) : 184A - 184A
  • [29] Prevalence of specific ulcer-associated H-pylori antibodies in volunteer and paid blood donors using the new RIBA(TM) H-pylori SIA.
    Dixit, V
    Bettis, K
    Yee, HF
    Quan, S
    Kovacs, T
    Brezina, M
    Abbey, H
    Martin, P
    DiNello, R
    Polito, A
    Gitnick, G
    [J]. GASTROENTEROLOGY, 1997, 112 (04) : A104 - A104
  • [30] DETECTION OF HCV RNA IN RIBA(TM)-REACTIVE SERUM SPECIMENS BY BDNA USING A SIMPLE CONCENTRATION PROCEDURE
    LAGLER, R
    DOUVILLE, C
    JOHNSON, P
    SANCHEZPESCADOR, R
    KURAMOTO, K
    [J]. HEPATOLOGY, 1994, 20 (04) : A367 - A367
12345